\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Preface}{}% 2
\BOOKMARK [0][-]{chapter*.3}{Table of Contents}{}% 3
\BOOKMARK [0][-]{chapter*.4}{List of Tables}{}% 4
\BOOKMARK [0][-]{chapter*.5}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.6}{List of Abbreviations}{}% 6
\BOOKMARK [0][-]{chapter*.7}{Acknowledgments}{}% 7
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{1.1 The Evolution of Molecular Diagnostics in Cancer}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.2}{1.2 Next-generation Sequencing Technologies}{chapter.1}% 10
\BOOKMARK [1][-]{section.1.3}{1.3 Applications of Next-generation Sequencing}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.3.1}{1.3.1 Targeted Sequencing}{section.1.3}% 12
\BOOKMARK [2][-]{subsection.1.3.2}{1.3.2 Whole Exome Sequencing}{section.1.3}% 13
\BOOKMARK [2][-]{subsection.1.3.3}{1.3.3 Whole Genome Sequencing}{section.1.3}% 14
\BOOKMARK [1][-]{section.1.4}{1.4 Bioinformatics Tools for Variant Calling}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.4.1}{1.4.1 Types of Genomic Alterations}{section.1.4}% 16
\BOOKMARK [2][-]{subsection.1.4.2}{1.4.2 Variant Calling Pipeline}{section.1.4}% 17
\BOOKMARK [2][-]{subsection.1.4.3}{1.4.3 Variant Calling Algorithms}{section.1.4}% 18
\BOOKMARK [2][-]{subsection.1.4.4}{1.4.4 Variant Curation and Interpretation}{section.1.4}% 19
\BOOKMARK [1][-]{section.1.5}{1.5 Germline Variant Calling in The Tumour Genome}{chapter.1}% 20
\BOOKMARK [2][-]{subsection.1.5.1}{1.5.1 Incidental Findings}{section.1.5}% 21
\BOOKMARK [2][-]{subsection.1.5.2}{1.5.2 Pharmacogenomic Variants}{section.1.5}% 22
\BOOKMARK [2][-]{subsection.1.5.3}{1.5.3 Challenges}{section.1.5}% 23
\BOOKMARK [1][-]{section.1.6}{1.6 Objectives}{chapter.1}% 24
\BOOKMARK [0][-]{chapter.2}{2 Characterization of Formalin-Induced DNA Damages}{}% 25
\BOOKMARK [1][-]{section.2.1}{2.1 Materials and Methods}{chapter.2}% 26
\BOOKMARK [2][-]{subsection.2.1.1}{2.1.1 Patient Samples}{section.2.1}% 27
\BOOKMARK [2][-]{subsection.2.1.2}{2.1.2 OncoPanel \(Solid Tumour NGS Panel\)}{section.2.1}% 28
\BOOKMARK [2][-]{subsection.2.1.3}{2.1.3 Sample Preparation, Library Construction, and Illumina Sequencing}{section.2.1}% 29
\BOOKMARK [2][-]{subsection.2.1.4}{2.1.4 Variant Calling Pipeline}{section.2.1}% 30
\BOOKMARK [2][-]{subsection.2.1.5}{2.1.5 Data Analysis}{section.2.1}% 31
\BOOKMARK [1][-]{section.2.2}{2.2 Results}{chapter.2}% 32
\BOOKMARK [2][-]{subsection.2.2.1}{2.2.1 Formalin fixation affects amplicon yield and sequencing results}{section.2.2}% 33
\BOOKMARK [1][-]{section.2.3}{2.3 Discussion}{chapter.2}% 34
\BOOKMARK [0][-]{chapter.3}{3 Concordance of Germline PGx Variants Between Blood and Tumours}{}% 35
\BOOKMARK [1][-]{section.3.1}{3.1 Materials and Methods}{chapter.3}% 36
\BOOKMARK [1][-]{section.3.2}{3.2 Results}{chapter.3}% 37
\BOOKMARK [2][-]{subsection.3.2.1}{3.2.1 Frequency of germline and somatic variants}{section.3.2}% 38
\BOOKMARK [2][-]{subsection.3.2.2}{3.2.2 Variant Allele Frequency Thresholds Can Maximize Sensitivity and Positive Predictive Value of Germline Variant Calling in Tumours}{section.3.2}% 39
\BOOKMARK [1][-]{section.3.3}{3.3 Discussion}{chapter.3}% 40
\BOOKMARK [0][-]{chapter.4}{4 Conclusion}{}% 41
\BOOKMARK [0][-]{chapter*.11}{Bibliography}{}% 42
\BOOKMARK [0][-]{appendix.A}{A Supporting Materials}{}% 43
